One of the key growth factors for the global NIPT testing market is the increasing preference for non-invasive procedures over invasive procedures.
Down syndrome affects 1 in 830 people in the United States and 1 in 920 people in Europe. Therefore, there is a large potential user base for NIPT testing. More and more people prefer NIPT testing because chorionic villus sampling (CVS) and amniocentesis can pose a risk of miscarriage. There is no risk of miscarriage when using the NIPT test method. More and more
doctors are choosing non-invasive prenatal testing that utilizes cell-free circulating DNA in maternal serum.
North America leads the global NIPT market due to the presence of major players in the US and high levels of awareness about NIPT testing. Europe is expected to rise to second place in terms of lead.
Moreover, Asia Pacific is expected to be the fastest growing region with China, Australia, India, Japan etc. The growth of the Asia Pacific NIPT market is driven by an increase in women in the region preferring later stages of pregnancy. BGI Diagnostics and Berry Genomics are two of the leading companies operating in the Chinese NIPT market, which is boosting the country’s growth. Moreover, the approval of BambniTest by the CFDA is spurring the market growth in this region.
*CFDA = China Food and Drug Administration
日本皮膚科学会 皮膚科専門医／日本医師会 産業医／東京衛生検査所 指導監督医
この記事は、 ヒロクリニックNIPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。
